Nivolumab Plus Relatlimab Demonstrates Sustained PFS Benefit in Advanced Melanoma

Source: Onc Live, June 2022

Fixed-dose nivolumab plus relatlimab-rmbw (Opdualag) elicited continued progression-free survival (PFS) benefit vs nivolumab (Opdivo) alone in patients with treatment-naïve, unresectable or metastatic melanoma, according to updated results from the phase 2/3 RELATIVITY-047 trial (NCT03470922) that were presented at the 2022 ASCO Annual Meeting.

Updated PFS data by blinded independent central review (BICR) showed, at a median follow-up of 19.3 months, sustained improvement in PFS with the combination. The median PFS was 10.22 months with nivolumab plus relatlimab (95% CI, 6.51-14.75) vs 4.63 months with nivolumab alone (95% CI, 3.48-6.44; HR, 0.78; 95% CI, 0.64-0.94). The PFS rates were also higher among patients who received the combination than in those who received nivolumab alone. At 12 months, the PFS rate for nivolumab plus relatlimab was 48.0% (95% CI, 42.5%-53.4%) vs 36.9% (95% CI, 31.7%-42.1%) for nivolumab alone. At 24 months, the PFS rate for those who received the combination was 38.5% (95% CI, 32.7%-44.2%) vs 29.0% (95% CI, 23.8%-34.4%) in those who received the monotherapy.

“Nivolumab plus relatlimab continued to demonstrate a sustained and consistent PFS benefit vs nivolumab [alone] with longer follow-up,” said Georgina V. Long, MD, PhD, FRACP, co-medical director, chair of Melanoma Medical Oncology and Translational Research, Melanoma Institute of Australia and Royal North Shore Hospital, The University of Sydney.

READ THE ORIGINAL FULL ARTICLE